Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JWCAR129 in Relapsed or Refractory Multiple Myeloma
NCT04677452Phase 1Unknown
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Dec 2020
- Primary completion
- Mar 2022
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JWCAR129 in multiple myeloma (MM), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Incidence of dose-limiting toxicities at 28 days, Incidence and severity of adverse events at 2 years and 1 more. Status: unknown.
02
Drugs
JWCAR129
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04677452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04677452.